Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy

Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we sought to investi...

Full description

Bibliographic Details
Main Authors: Vincenza Conteduca, Orazio Caffo, Emanuela Scarpi, Pierangela Sepe, Luca Galli, Lucia Fratino, Francesca Maines, Vincenzo Emanuele Chiuri, Matteo Santoni, Elisa Zanardi, Francesco Massari, Ilaria Toma, Cristian Lolli, Giuseppe Schepisi, Andrea Sbrana, Stefania Kinspergher, Maria Concetta Cursano, Chiara Casadei, Caterina Modonesi, Daniele Santini, Giuseppe Procopio, Ugo De Giorgi
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Journal of Clinical Medicine
Subjects:
prostate cancer
androgen deprivation therapy
abiraterone
enzalutamide
autoimmunity
prognosis
Online Access:https://www.mdpi.com/2077-0383/9/6/1950

Internet

https://www.mdpi.com/2077-0383/9/6/1950

Similar Items